The Journal of Urology
Volume 182, Issue 5 , Pages 2112-2122 , November 2009

A Framework for the Identification of Men at Increased Risk for Prostate Cancer

  • Monique J. Roobol

      Affiliations

    • Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    • Nothing to disclose.
    • ,
  • Fritz H. Schröder

      Affiliations

    • Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    • Financial interest and/or other relationship with Ferring, GSK, Bayer-Schering, Gen-Probe and Beckman-Coulter.
    • Corresponding Author InformationCorrespondence: Erasmus MC, University Medical Centre, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands (telephone: +31 10 703 4328; FAX: +31 10 703 5315)
    • ,
  • E. David Crawford

      Affiliations

    • Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • Financial interest and/or other relationship with GSK.
    • ,
  • Stephen J. Freedland

      Affiliations

    • Department of Surgery, Durham VA Medical Center and the Departments of Surgery and Pathology, Division of Urologic Surgery, Duke Prostate Center, Duke University Medical Center, Durham, North Carolina
    • Nothing to disclose.
    • ,
  • A. Oliver Sartor

      Affiliations

    • Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana
    • Financial interest and/or other relationship with GSK.
    • ,
  • Neil Fleshner

      Affiliations

    • University Health Network, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Aventis, Novartis, Pfizer and Bioadvantex Pharma.
    • ,
  • Gerald L. Andriole

      Affiliations

    • Division of Urologic Surgery, Washington University in St. Louis, St. Louis, Missouri
    • Financial interest and/or other relationship with Aeterna Zentaris, Envisioneering, Ferring Pharmaceutical, GlaxoSmithKline, Nema Steba, Onconome, Veridex LLC, Viking Medical Systems and Zeneca.

Received 27 January 2009

References 

  1. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66
  2. Stenman UH, Hakama M, Knekt P, et al. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594
  3. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289
  4. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521
  5. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25:431
  6. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001;58:411
  7. Antenor JA, Han M, Roehl KA, et al. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol. 2004;172:90
  8. Loeb S, Roehl KA, Antenor JA, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67:316
  9. Aus G, Damber JE, Khatami A, et al. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med. 2005;165:1857
  10. Schroder FH, Roobol MJ, Andriole G, et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol. 2009;181:69
  11. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215
  12. Raaijmakers R, Blijenberg BG, Finlay JA, et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol. 2004;171:2245
  13. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910
  14. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386
  15. Karazanashvili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol. 2003;169:445
  16. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008;26:835
  17. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529
  18. Etzioni RD, Ankerst DP, Weiss NS, et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer? (A critical appraisal of the evidence). J Natl Cancer Inst. 2007;99:1510
  19. Schröder FH, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008;54:274
  20. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101:2371
  21. Bostwick DG, Qian J, Civantos F, et al. Does finasteride alter the pathology of the prostate and cancer grading?. Clin Prostate Cancer. 2004;2:228
  22. Canby-Hagino E, Hernandez J, Brand TC, et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/ml. Urology. 2007;70:748
  23. Roobol MJ, Schroder FH, Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate. 2006;66:604
  24. Sajadi KP, Kim T, Terris MK, et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology. 2007;70:691
  25. Briganti A, Chun FK, Suardi N, et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer. 2007;43:2669
  26. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol. 2001;166:1679
  27. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314
  28. Steuber T, Vickers A, Haese A, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer. 2007;120:1499
  29. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542
  30. Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008;71:1016
  31. Carter HB, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992;52:3323
  32. Roobol M. (I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. Eur Urol. 2008;53:852
  33. Roobol M. (II) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. Eur Urol. 2008;53:854
  34. Steuber T, O'Brien MF, Lilja H. Serum markers for prostate cancer: a rational approach to the literature. Eur Urol. 2008;54:31
  35. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008;54:1951
  36. Ostrander EA, Udler MS. The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev. 2008;17:1843
  37. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol. 2004;17:360
  38. Bostwick DG, Meiers I. Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med. 2006;130:952
  39. Epstein JI. What's new in prostate cancer disease assessment in 2006?. Curr Opin Urol. 2006;16:146
  40. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175:820
  41. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268
  42. Vickers AJ, Ulmert D, Serio AM, et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer. 2007;121:2212
  43. Gosselaar C, Roobol MJ, van den Bergh RC, et al. Digital rectal examination and the diagnosis of prostate cancer—a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol. 2009;55:139
  44. Schroder FH, Raaijmakers R, Postma R, et al. 4-Year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol. 2005;174:489
  45. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289:2695
  46. Chun FK, Karakiewicz PI, Huland H, et al. Role of nomograms for prostate cancer in 2007. World J Urol. 2007;25:131

 Supported by GlaxoSmithKline.

 See Editorial on page 2101.

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2538 and 2539.

PII: S0022-5347(09)01742-X

doi: 10.1016/j.juro.2009.07.018

The Journal of Urology
Volume 182, Issue 5 , Pages 2112-2122 , November 2009

Article Tools

* Image Usage & Resolution